Blood Testing Market By Product Type (Reagents and Kits, Instruments and Software), By Test Type (Complete Blood Count (CBC), Blood Glucose Test, Lipid Panel Testing, Hemoglobin A1C, BUN (Blood Urea Nitrogen) Testing, Creatinine, Cortisol, COVID-19 Tests and Others), By Application (Disease Diagnosis, Health Screening, Monitoring and Transfusion Medicine), By Method (Manual and Automated), and By End User (Hospitals, Diagnostic Laboratories, Home Care Settings, Research Institutions and Blood Banks), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Blood Testing market accounted for USD 97.5 Billion in 2024 and is expected to reach USD 218.2 Billion by 2035, growing at a CAGR of around 7.6% between 2025 and 2035.  Blood testing involves a wide range of diagnostic tests using blood samples to detect diseases, monitor health, and evaluate organ function. Moreover, the blood testing market includes genetic testing for inherited conditions, therapeutic drug monitoring for personalized medication management, and biomarker testing to assess cancer progression or response. These tests include complete blood counts, biochemical tests, and infectious disease screenings. Key factors driving the blood testing market include the growing demand for early disease detection, advancements in testing technologies, and an overall shift towards preventive healthcare. Personalized medicine, self-testing, and home kits are changing the landscape, making testing more convenient and efficient. Overall, blood testing plays a crucial role in modern healthcare and disease management.

Report Scope:

Market Dynamics

• The Home Testing Kit Revolution Driving the Future of Blood Testing
  The blood testing market has experienced significant growth due to the increasing popularity of home testing kits. These kits offer ease and convenience for consumers, allowing patients to monitor their health conditions, track chronic diseases, and conduct routine screenings from the comfort of their homes. This trend has been further accelerated by the COVID-19 pandemic, which has highlighted the importance of remote healthcare solutions. Advancements in testing technology, such as glucose monitoring and hormonal level testing, have empowered patients to take control of their health. Furthermore, continuous improvements in kit usability and accuracy have led to increased adoption in the market. For instance, CDC reports state that the use of at-home tests peaked in January 2022, when 11.0% of those surveyed said they had used them in the 30 days prior.
• Challenges in Sample Collection and Handling Hinder Blood Testing Market Growth
  One of the main challenges in the blood testing market is sample collection and handling. Improper techniques can lead to incorrect results and compromise the validity of the tests. Contamination, improper storage, and delayed transportation of samples can affect the integrity of the blood sample. Different healthcare providers use varying collection methods, leading to inconsistent outcomes. This not only undermines patient confidence in diagnosis but also results in unnecessary testing repetitions and increased healthcare costs. To address these challenges and improve the reliability of blood tests, it is crucial to establish standardized protocols and provide training on sample collection.
• Biomarker-Specific Panels Leading the Future of Blood Testing
  Biomarker-specific panels are a promising opportunity for the blood testing market related to targeted diagnosis and monitoring of specific diseases or health conditions. This can help in measuring multiple biomarkers associated with a particular disease, such as cancer, cardiovascular disorders, or autoimmune diseases, and predict the occurrence of diseases much earlier than it manifests. Tailored panels are likely to enhance patient outcomes by being able to provide the precise information necessary for making the treatment decision. Diagnostic companies will open avenues for innovation and expansion of specialized panels within an era of personalized medicine, most in demand in healthcare.

Industry Experts Opinion

“Blood tests for Alzheimer’s disease promise to provide an earlier and more accurate diagnosis for many patients with cognitive impairment.  However, some currently available blood tests are extremely accurate while others are a little better than flipping a coin.  We worked with many different stakeholders to develop minimum standards for the accuracy of these blood tests, because we know that a timely and accurate diagnosis of Alzheimer’s disease has a major impact on a patient’s life,” 

• Dr. Suzanne Schindler, Department of Neurology, Washington University School of Medicine and BBM Workgroup Co-Lead.

“With the strategic acquisition of Think Health Diagnostics, we are well-positioned to expand our footprint in pre-policy medical checkups for the insurance segment. This will allow us to give our insurance partners a one-stop solution for blood and ECG testing and further deepen our presence in the Pre Policy Medical Checkup and Annual Health Checkup market,”

• Rahul Guha, MD and CEO of Thyrocare Technologies

Segment Analysis

Based on the product type, the Blood Testing market has been classified into reagents and kits, instruments, and software. The Reagents and kits are the most popular products in the blood testing market because they are essential for performing various tests, such as hematology and biochemistry, in laboratories. As a result, there is steady demand and a high turnover. Technology advancements have also increased their efficacy and increased their dependability.

Based on the Test type, the Blood Testing market has been classified into Complete Blood Count (CBC), Blood Glucose Test, Lipid Panel Testing, A1C (Hemoglobin A1C) BUN (Blood Urea Nitrogen) Testing, Creatinine, Cortisol, COVID-19 Tests and Others Glucose testing leads the test type segment. Glucose testing is significant in health care since it allows physicians to track and manage conditions such as diabetes, hypoglycemia, and hyperglycemia. The worldwide prevalence of diabetes, along with heightened attention to preventive care, has significantly driven up glucose testing demand. Further, technologies have been developed with innovative glucose monitoring devices such as continuous glucose monitors and point-of-care test kits. This brings about better accuracy and convenience in testing for glucose.

Regional Analysis

The North American region has been the largest market for blood testing due to the high advance healthcare infrastructures, high prevalence of chronic diseases, and great research and development investment in the region. Dominance by major market players and adoption of innovative technologies have also contributed to its present dominance. An additional factor is a growing focus on preventive care and the early detection of illnesses that further drives the need for a variety of blood tests, which earns North America an apex of diagnostics. The U.S. is the largest shareholder due to a sound regulatory framework. In this region, point-of-care testing is growing rapidly with fast results, which in turn contributes positively to patient management. The inclusion of telehealth further streamlines access to blood testing services, mainly post-pandemic. For instance, The USA conducted around 4.5 million tests between February and April 2020 compared to the recommended daily test of 5–20 million.   

The Asia-Pacific region will emerge as the blood testing market with the most explosive growth. Increased expenditure on healthcare, a rising population, and increased awareness of health issues propel markets in the region to growth. Urbanization is at a rapid pace, and the access to health care in China and India has improved significantly, thus increasing the demand for blood testing. This is further adding to this region's boom in point-of-care testing and new diagnostic technologies. The market, therefore, becomes even more attractive for expansion and investment over the coming years.

Competitive Landscape

The blood testing market is highly competitive with various featuring key players. Key operating players in the Blood Testing market are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Danaher Corporation, Siemens Healthineers Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Becton, Dickinson and Company (BD), Grifols, S.A., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings bioMérieux, Hologic, Inc., Sysmex Corporation, Cepheid Corporation and PerkinElmer, Inc. For instance, in Oct., 2022, A co-exclusive commercial agreement was recently announced by BD (Becton, Dickinson and Company) (NYSE: BDX), a top global provider of medical technology, and Magnolia Medical Technologies, Inc. The goal of the agreement is to assist US hospitals in lowering blood culture contamination to increase testing accuracy and, ultimately, improve clinical outcomes. This partnership demonstrates their dedication to improving test accuracy, which will eventually result in better clinical outcomes and a more stable position in the changing market.

Blood Testing Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In November, 2023, The Food and Drug Administration (FDA) approved a blood test for marketing that looks for hereditary genetic alterations that could raise a person's risk of getting specific types of cancer. An individual's blood sample is examined by the Invitae Common Hereditary Cancers Panel test to check for alterations in 47 genes associated with hereditary cancer types.
• In November 2023, Quest Diagnostics and Universal DX Announced Strategic Partnership to Offer Advanced Colorectal Cancer Screening Blood Tests to US Patients and Providers
• On Jan. 30, 2023, the world leader in pharmaceuticals and diagnostics, Roche and Jana Care, Inc., an early-stage at-home In Vitro Diagnostics (IVD) company, announced a collaboration agreement for their digitally connected blood testing platform. This will allow patients to self-administer vital blood tests at home and physicians to review the test results remotely.

Report Coverage:

By Product Type

• Reagents and Kits
• Instruments
• Software

By Test Type  

• Complete Blood Count (CBC)
• Blood Glucose Test
• Lipid Panel Testing
• A1C (Hemoglobin A1C)
• BUN (Blood Urea Nitrogen) Testing
• Creatinine
• Cortisol
• COVID-19 Tests
• Others

By Application

• Disease Diagnosis
• Health Screening
• Monitoring
• Transfusion Medicine

By Method

• Manual
• Automated

By End User

• Hospitals
• Diagnostic Laboratories
• Home Care Settings
• Research Institutions
• Blood Banks

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Siemens Healthineers
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Becton, Dickinson and Company (BD)
• Grifols, S.A.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings (LabCorp)
• bioMérieux
• Hologic, Inc.
• Sysmex Corporation
• Cepheid Corporation
• PerkinElmer, Inc.

Frequently Asked Questions (FAQs)